HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

DSGN

Design Therapeutics Inc

Last Close
Sep 15  •  04:00PM ET
5.86
Dollar change
-0.17
Percentage change
-2.82 %
Healthcare • Biotechnology • USA • NASD
Peers: PFE REGN VRTX MRNA BNTX CRSP EDIT NTLA SGMO BEAM
 | Held by: IWM VTI IWN VXF IBB SCHA VTWO FESM IWC ONEQ
Scroll to Statements
IndexRUT P/E- EPS (ttm)-1.12 Insider Own45.37% Shs Outstand56.95M Perf Week0.69%
Market Cap333.73M Forward P/E- EPS next Y-1.22 Insider Trans-2.13% Shs Float31.11M Perf Month13.57%
Enterprise Value119.40M PEG- EPS next Q-0.34 Inst Own45.84% Short Float11.31% Perf Quarter52.60%
Income-63.49M P/S- EPS this Y-51.89% Inst Trans3.13% Short Ratio27.65 Perf Half Y24.55%
Sales0.00M P/B1.57 EPS next Y8.98% ROA-25.78% Short Interest3.52M Perf YTD-5.02%
Book/sh3.74 P/C1.54 EPS next 5Y-17.11% ROE-26.77% 52W High7.77 -24.58% Perf Year12.26%
Cash/sh3.80 P/FCF- EPS past 3/5Y-10.99% -88.52% ROIC-29.65% 52W Low2.60 125.38% Perf 3Y-74.85%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility8.69% 8.63% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-24.60% Oper. Margin- ATR (14)0.45 Perf 10Y-
Dividend Ex-Date- Quick Ratio25.13 Sales Y/Y TTM- Profit Margin- RSI (14)55.34 Recom2.33
Dividend Gr. 3/5Y- - Current Ratio25.13 EPS Q/Q-60.96% SMA203.23% Beta1.62 Target Price7.33
Payout- Debt/Eq0.01 Sales Q/Q- SMA5022.28% Rel Volume0.90 Prev Close6.03
Employees54 LT Debt/Eq0.01 EarningsAug 07 AMC SMA20026.84% Avg Volume127.20K Price5.86
IPOMar 26, 2021 Option/ShortYes / Yes EPS/Sales Surpr.-3.03% - Trades Volume114,313 Change-2.82%
Date Action Analyst Rating Change Price Target Change
May-07-24Upgrade Piper Sandler Neutral → Overweight $6 → $12
Nov-14-23Downgrade Piper Sandler Overweight → Neutral $42 → $6
Aug-15-23Downgrade Wedbush Outperform → Neutral $19 → $6
Aug-15-23Downgrade SVB Securities Outperform → Market Perform $6
Aug-15-23Downgrade RBC Capital Mkts Outperform → Sector Perform $23 → $7
May-04-23Upgrade Goldman Sell → Neutral $6
Jun-10-22Initiated Wedbush Outperform $21
May-02-22Initiated RBC Capital Mkts Outperform $30
Jan-19-22Initiated Goldman Sell $10
Apr-20-21Initiated SVB Leerink Outperform $36
Show Previous Ratings
Sep-10-25 04:01PM
Design Therapeutics Appoints Justin Gover to Board of Directors
(GlobeNewswire) -7.68%
Aug-27-25 08:00AM
Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
(GlobeNewswire)
Aug-07-25 04:01PM
Design Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Second Quarter 2025 Financial Results
(GlobeNewswire) -8.74% +7.81%
Jun-04-25 07:00AM
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
(GlobeNewswire)
May-28-25 08:00AM
Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference
(GlobeNewswire)
08:00AM Loading…
May-13-25 08:00AM
Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference
(GlobeNewswire)
May-07-25 04:01PM
Design Therapeutics Highlights Momentum Across Lead GeneTAC Programs and Reports First Quarter 2025 Financial Results
(GlobeNewswire) -8.26% +5.71%
May-02-25 07:58AM
Design Therapeutics reports positive outcomes from trial of DT-168 eye drops
(Clinical Trials Arena)
May-01-25 08:00AM
Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy
(GlobeNewswire)
Apr-21-25 04:01PM
Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025
(GlobeNewswire) +10.31%
Apr-17-25 08:00AM
Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer
(GlobeNewswire)
07:00AM
Bright Peak Therapeutics Appoints John Schmid to its Board of Directors
(GlobeNewswire)
Mar-12-25 12:00PM
Design Therapeutics (DSGN) Upgraded to Buy: Here's Why
(Zacks) -6.94%
Mar-10-25 07:07AM
Design Therapeutics Highlights Progress Across Lead GeneTAC Programs and Reports Fourth Quarter and Full Year 2024 Financial Results
(GlobeNewswire)
Mar-03-25 08:00AM
Design Therapeutics to Participate in Leerink's Global Healthcare Conference
(GlobeNewswire) -7.00%
08:00AM Loading…
Nov-13-24 08:00AM
Design Therapeutics to Participate in Multiple Upcoming Investor Conferences
(GlobeNewswire) +8.54%
Nov-07-24 04:01PM
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio
(GlobeNewswire)
Sep-10-24 08:00AM
Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference
(GlobeNewswire) +15.69%
Aug-21-24 09:55AM
Wall Street Analysts Think Design Therapeutics (DSGN) Could Surge 39.72%: Read This Before Placing a Bet
(Zacks)
Aug-05-24 08:00AM
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC Portfolio
(GlobeNewswire)
May-22-24 08:50PM
The 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit Gains
(InvestorPlace)
May-10-24 03:36PM
Design Therapeutics Inc (DSGN) Q1 2024 Earnings: A Detailed Financial and Strategic Review
(GuruFocus.com)
May-08-24 11:55PM
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q1 2024
(InvestorPlace)
04:05PM
Design Therapeutics Announces First Quarter 2024 Financial Results and Highlights Upcoming Program Milestones
(GlobeNewswire)
May-07-24 07:12AM
--Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral
(MT Newswires) +28.49%
06:30AM
Design Therapeutics to Participate in the 2024 RBC Capital Markets Global Healthcare Conference
(GlobeNewswire)
Mar-20-24 10:31AM
Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript
(Insider Monkey) +11.97%
06:58AM
Q4 2023 Design Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Mar-19-24 08:53PM
DSGN Stock Earnings: Design Therapeutics Beats EPS for Q4 2023
(InvestorPlace)
05:33PM
Design Therapeutics Inc (DSGN) Reports Full Year 2023 Financial Results and Pipeline Progress
(GuruFocus.com)
04:01PM Loading…
04:01PM
Design Therapeutics Outlines Progress Across GeneTAC Platform and Announces Fourth Quarter and Full Year 2023 Financial Results
(GlobeNewswire)
Mar-12-24 06:30AM
Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update
(GlobeNewswire)
Dec-18-23 12:00PM
Design Therapeutics, Inc. (DSGN) Upgraded to Buy: Here's What You Should Know
(Zacks)
Nov-14-23 07:28PM
Design Therapeutics Inc (DSGN) Reports Q3 2023 Financials, Plans Strategic Update
(GuruFocus.com) +11.71%
Nov-13-23 04:05PM
Design Therapeutics Reports Third Quarter 2023 Financial Results and Plans for a Comprehensive Portfolio Update in Early 2024
(GlobeNewswire)
Aug-15-23 03:02PM
Why Shares of Design Therapeutics Are Plummeting on Tuesday
(Motley Fool) -70.46%
09:59AM
Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls
(The Fly)
02:34AM
4 big analyst cuts: Urban Outfitters has 'limited' EPS upside, per Citi
(Investing.com)
Aug-14-23 04:05PM
Design Therapeutics Provides Pipeline Update and Reports Second Quarter 2023 Financial Results
(GlobeNewswire)
04:01PM
Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia
(GlobeNewswire)
Jun-18-23 08:03AM
Pleasing Signs As A Number Of Insiders Buy Design Therapeutics Stock \
(Simply Wall St.)
May-31-23 06:30AM
Design Therapeutics to Present at the 2023 Jefferies Healthcare Conference
(GlobeNewswire) -6.01%
May-09-23 04:05PM
Design Therapeutics Provides Pipeline Updates and Reports First Quarter 2023 Financial Results
(GlobeNewswire) -11.66%
May-08-23 06:05AM
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
(Simply Wall St.)
Apr-24-23 06:30AM
Design Therapeutics to Present Preclinical Data on its GeneTAC Small Molecule, DT-168, for the Treatment of Fuchs Endothelial Corneal Dystrophy at ARVO 2023
(GlobeNewswire)
Apr-11-23 09:55AM
Why Design Therapeutics (DSGN) Stock Is Going Nowhere But Down
(InvestorPlace)
Apr-04-23 02:47PM
Down More Than 60%: Analysts Say Buy These 3 Beaten-Down Stocks Before They Rebound
(TipRanks) -7.32%
Mar-14-23 04:05PM
Design Therapeutics Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2022 Financial Results
(GlobeNewswire)
Mar-09-23 06:33AM
Daily Vickers Top Insider Picks for 03/09/2023
(Argus Research)
Feb-08-23 06:30AM
Design Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
(GlobeNewswire) -8.79%
Dec-21-22 06:46AM
Daily Vickers Top Buyers & Sellers for 12/21/2022
(Argus Research) +5.33%
Dec-14-22 05:15AM
Independent Director Rodney Lappe Just Bought 15% More Shares In Design Therapeutics, Inc. (NASDAQ:DSGN)
(Simply Wall St.)
Dec-07-22 04:01PM
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
(GlobeNewswire) -6.00% -33.33%
Nov-28-22 10:37AM
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
(Simply Wall St.)
Nov-03-22 04:05PM
Design Therapeutics Highlights Pipeline Progress and Upcoming Milestones and Reports Third Quarter 2022 Financial Results
(GlobeNewswire)
Oct-17-22 04:05PM
Design Therapeutics to Present Preclinical Data Highlighting the Potential of its GeneTAC Small Molecule, DT-216, for the Treatment of Friedreich Ataxia at ICAR 2022
(GlobeNewswire)
Sep-22-22 06:30AM
Design Therapeutics to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
(GlobeNewswire)
Aug-08-22 04:05PM
Design Therapeutics Highlights Upcoming Milestones and Reports Second Quarter 2022 Financial Results
(GlobeNewswire)
Aug-03-22 06:30AM
Design Therapeutics to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
(GlobeNewswire) +6.33%
Jun-21-22 09:57AM
Companies Like Design Therapeutics (NASDAQ:DSGN) Are In A Position To Invest In Growth
(Simply Wall St.) +6.24%
Jun-01-22 06:30AM
Design Therapeutics to Present at the 2022 Jefferies Healthcare Conference
(GlobeNewswire)
May-09-22 04:05PM
Design Therapeutics Highlights Clinical and Research Progress and Reports First Quarter 2022 Financial Results
(GlobeNewswire)
Mar-30-22 06:30AM
Design Therapeutics Completes Dosing in First Patient Cohort of Phase 1 Trial of DT-216 GeneTAC Molecule for the Treatment of Friedreich Ataxia
(GlobeNewswire)
Mar-23-22 02:53PM
Design Therapeutics, Inc. (NASDAQ:DSGN) insiders placed bullish bets worth US$1.2m in the last 12 months
(Simply Wall St.)
Mar-10-22 04:02PM
Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results
(GlobeNewswire)
Mar-09-22 06:30AM
Design Therapeutics Announces Preclinical Data Highlighting Novel GeneTAC Therapy for the Treatment of Fuchs Endothelial Corneal Dystrophy to be Presented at ARVO 2022
(GlobeNewswire) +9.41%
Feb-28-22 04:05PM
Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC Molecule for Friedreich Ataxia
(GlobeNewswire)
Feb-10-22 06:30AM
Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
(GlobeNewswire) +7.02%
Feb-01-22 04:05PM
Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer
(GlobeNewswire)
Jan-19-22 12:51PM
Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating
(Benzinga) -5.86%
Dec-23-21 05:00AM
Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans
(Simply Wall St.) +5.09%
Nov-09-21 04:05PM
Design Therapeutics Reports Pipeline Progress and Third Quarter 2021 Results
(GlobeNewswire)
Sep-24-21 07:55AM
Design Therapeutics, Inc. (NASDAQ:DSGN) insiders placed bullish bets worth US$1.2m in the last 12 months
(Simply Wall St.)
Sep-08-21 06:30AM
Design Therapeutics Announces Positive Preclinical Data Highlighting Disease-Modifying Potential of its Novel DM1 GeneTACs as a Treatment for Myotonic Dystrophy Type-1
(GlobeNewswire)
Sep-03-21 07:33AM
4 Stocks Insiders Are Buying
(Benzinga)
Aug-09-21 04:05PM
Design Therapeutics Reports GeneTAC Portfolio Progress and Second Quarter 2021 Results
(GlobeNewswire) +6.19%
Jun-26-21 04:30AM
We're Hopeful That Design Therapeutics (NASDAQ:DSGN) Will Use Its Cash Wisely
(Simply Wall St.)
Jun-07-21 04:10PM
Design Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
(GlobeNewswire)
04:05PM
Design Therapeutics Expands Board of Directors with Key Appointments
(GlobeNewswire)
May-10-21 04:05PM
Design Therapeutics Announces Business Highlights and Reports First Quarter 2021 Financial Results
(GlobeNewswire) -6.82%
Mar-30-21 04:05PM
Design Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
(GlobeNewswire) -13.20%
Mar-25-21 11:56PM
Design Therapeutics Announces Pricing of Initial Public Offering
(GlobeNewswire)
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
William ArsaniDirectorAug 13 '25Sale5.25562,6272,953,7921,000,000Aug 14 04:15 PM
Logos Opportunities Fund II LPDirectorAug 13 '25Proposed Sale4.98217,6271,083,783Aug 13 08:05 PM
Logos Global Master Fund LPDirectorAug 13 '25Proposed Sale4.98345,0001,718,100Aug 13 08:04 PM
Prasad DeepaDirectorDec 18 '24Sale6.273,80623,86420,000Dec 19 06:30 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.